The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2019 | Haploidentical transplantation for AML with MRD at transplantation
Stefan Ciurea, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the major findings in his study of haploidentical transplantation for acute myeloid leukemia (AML) patients with measurable residual disease (MRD) at transplantation. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.
